The State-of-the-Art of Immunotherapy in the Triple-Negative Breast Cancer Treatment: Main Drugs, Combinations, Mechanisms of Action and Future Perspectives

Detalhes bibliográficos
Autor(a) principal: Tavares, Dione Fernandes
Data de Publicação: 2021
Outros Autores: Cardoso-Júnior, Laércio Moreira, Ribeiro, Victoria Chaves, Britto, Renata Lopes
Tipo de documento: Artigo
Idioma: por
eng
Título da fonte: Revista Brasileira de Cancerologia (Online)
Texto Completo: https://rbc.inca.gov.br/index.php/revista/article/view/1014
Resumo: Introduction: Breast cancer is the most commonly diagnosed cancer in women and is one of the leading causes of death from cancer in women worldwide. Despite, or perhaps because of its aggressive nature and current lack of targeted treatments, significant basic research and clinical trials are being conducted to provide new treatment options. Historically, chemotherapy has been the only viable systemic treatment option for early and advanced diseases. However, recently published clinical trials have shown that immunotherapy plays an important role in the treatment paradigm of this devastating clinical condition. Objective: To demonstrate the state-of-the-art results of immunotherapy in the treatment of triple-negative breast cancer. Method: An integrative literature review was carried out between January/2020 and March/2020, in PubMed, SciELO, International Clinical Trials Registry Platform and LILACS databases, using the keywords “Immunotherapy”, “Breast Cancer”, and “Triple Negative Breast Cancer” and its respective correspondents in Portuguese. Results: 465 articles were found; of those, 457 were excluded after applying the methodological criteria. Thus, 8 articles that met the inclusion criteria, showing the main therapeutic agents used, mechanisms of action and therapeutic combinations, remained. 25 clinical trials were found in progress on the International Clinical Trials Registry Platform. Conclusion: Although immunotherapy is somewhat recent, its results with PARP, PD-1 and PD-L1 inhibitors have shown satisfactory results. New trials with subgroups stratified according to specific tumor biomarkers are needed in order to assess if some subgroups have greater benefit to treatment.
id INCA-1_84f1b9074ebaf63be609fa3fb5d0b4e2
oai_identifier_str oai:rbc.inca.gov.br:article/1014
network_acronym_str INCA-1
network_name_str Revista Brasileira de Cancerologia (Online)
repository_id_str
spelling The State-of-the-Art of Immunotherapy in the Triple-Negative Breast Cancer Treatment: Main Drugs, Combinations, Mechanisms of Action and Future PerspectivesEl Estado del Arte de la Inmunoterapia en el Tratamiento del Cáncer de Mama Triple Negativo: Principales Fármacos, Asociaciones, Mecanismos de Acción y Perspectivas de FuturoO Estado da Arte da Imunoterapia no Tratamento do Câncer de Mama Triplo-Negativo: Principais Drogas, Associações, Mecanismos de Ação e Perspectivas FuturasImunoterapiaNeoplasias da Mama/terapiaNeoplasias de Mama Triplo NegativasBiomarcadoresImmunotherapyBreast Neoplasms/therapyTriple Negative Breast NeoplasmsBiomarkersInmunoterapiaNeoplasias de la Mama/terapiaNeoplasias de la Mama Triple NegativasBiomarcadoresIntroduction: Breast cancer is the most commonly diagnosed cancer in women and is one of the leading causes of death from cancer in women worldwide. Despite, or perhaps because of its aggressive nature and current lack of targeted treatments, significant basic research and clinical trials are being conducted to provide new treatment options. Historically, chemotherapy has been the only viable systemic treatment option for early and advanced diseases. However, recently published clinical trials have shown that immunotherapy plays an important role in the treatment paradigm of this devastating clinical condition. Objective: To demonstrate the state-of-the-art results of immunotherapy in the treatment of triple-negative breast cancer. Method: An integrative literature review was carried out between January/2020 and March/2020, in PubMed, SciELO, International Clinical Trials Registry Platform and LILACS databases, using the keywords “Immunotherapy”, “Breast Cancer”, and “Triple Negative Breast Cancer” and its respective correspondents in Portuguese. Results: 465 articles were found; of those, 457 were excluded after applying the methodological criteria. Thus, 8 articles that met the inclusion criteria, showing the main therapeutic agents used, mechanisms of action and therapeutic combinations, remained. 25 clinical trials were found in progress on the International Clinical Trials Registry Platform. Conclusion: Although immunotherapy is somewhat recent, its results with PARP, PD-1 and PD-L1 inhibitors have shown satisfactory results. New trials with subgroups stratified according to specific tumor biomarkers are needed in order to assess if some subgroups have greater benefit to treatment.Introducción: El cáncer de mama es el más comúnmente diagnosticado en las mujeres y es una de las principales causas de muerte por cáncer en mujeres de todo el mundo. A pesar de, o quizás debido a su naturaleza agresiva y la falta de tratamientos dirigidos actuales, investigaciones clínicas y de laboratorio significativas están proporcionando opciones de tratamiento diferenciadas. Históricamente, la quimioterapia ha sido la única opción viable para el tratamiento sistémico de enfermedades tempranas y avanzadas. Sin embargo, los ensayos clínicos publicados recientemente han demostrado que la inmunoterapia desempeña un papel importante en el paradigma del tratamiento de esta condición devastadora. Objetivo: Demostrar el estado del arte de la inmunoterapia en el cáncer de mama triple negativo. Método: Revisión integradora entre enero/2020 y marzo/2020, utilizando las bases de datos PubMed, SciELO, International Clinical Trials Registry Platform y LILACS, empleando las palabras clave “Inmunoterapia”, “Cáncer de mama” y “Cáncer de mama triple negativo” y los respectivos términos en inglés. Resultados: Se encontraron 465 artículos; de estos, 457 fueron excluidos después de aplicar los criterios metodológicos. Así, quedaron 8 artículos que cumplían los criterios, que mostraban los principales agentes terapéuticos utilizados, mecanismos de acción y combinaciones terapéuticas. Se encontraron 25 ensayos clínicos en progreso en la plataforma International Clinical Trials Registry Platform. Conclusión: Aunque la inmunoterapia es algo reciente, sus resultados con inhibidores de PARP, PD-1 y PD-L1 han mostrado resultados satisfactorios. Se necesitan nuevos ensayos con subgrupos estratificados según biomarcadores tumorales específicos para evaluar si algún subgrupo tiene un mayor beneficio.Introdução: O câncer de mama e o mais comumente diagnosticado em mulheres e uma das principais causas de morte por câncer em mulheres em todo o mundo. Apesar, ou talvez por causa, de sua natureza agressiva e da falta de tratamentos direcionados atuais, pesquisas clínicas e laboratoriais significativas estão fornecendo opções de tratamento diferenciadas. Historicamente, a quimioterapia tem sido a única opção viável de tratamento sistêmico para doenças precoces e avançadas. No entanto, ensaios clínicos publicados recentemente mostraram que a imunoterapia tem um papel importante no paradigma de tratamento dessa condição devastadora. Objetivo: Demonstrar o estado da arte da imunoterapia no tratamento do câncer de mama triplo-negativo. Método: Revisão integrativa de literatura, entre janeiro/2020 a marco/2020, a partir das bases de dados PubMed, SciELO, International Clinical Trials Registry Platform e LILACS, por meio dos descritores “Imunoterapia”, “Neoplasias da mama” e “Neoplasias de mama triplo negativas” e seus respectivos correspondentes em inglês. Resultados: Foram encontrados 465 artigos; destes, 457 foram excluídos após aplicação dos critérios metodológicos. Assim, restaram oito artigos que atendiam aos critérios de inclusão, demonstrando os principais agentes terapêuticos utilizados, mecanismos de ação e combinações terapêuticas. Encontraram-se 25 ensaios clínicos em andamento na plataforma de registro de ensaios clínicos International Clinical Trials Registry Platform. Conclusão: Embora a imunoterapia seja algo recente, seus resultados com agentes inibidores da PARP, PD-1 e PD-L1 demonstraram resultados satisfatórios. Novos ensaios com subgrupos estratificados de acordo com biomarcadores tumorais específicos são necessários, a fim de avaliar se algum subgrupo tem maior benefício ao tratamento.INCA2021-03-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionRevisão de literaturaapplication/pdfapplication/pdfhttps://rbc.inca.gov.br/index.php/revista/article/view/101410.32635/2176-9745.RBC.2021v67n2.1014Revista Brasileira de Cancerologia; Vol. 67 No. 2 (2021): Apr./May/June; e-061014Revista Brasileira de Cancerologia; Vol. 67 Núm. 2 (2021): abr./mayo/jun.; e-061014Revista Brasileira de Cancerologia; v. 67 n. 2 (2021): abr./maio/jun.; e-0610142176-9745reponame:Revista Brasileira de Cancerologia (Online)instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)instacron:INCAporenghttps://rbc.inca.gov.br/index.php/revista/article/view/1014/979https://rbc.inca.gov.br/index.php/revista/article/view/1014/1358Copyright (c) 2021 Revista Brasileira de Cancerologiainfo:eu-repo/semantics/openAccessTavares, Dione FernandesCardoso-Júnior, Laércio MoreiraRibeiro, Victoria Chaves Britto, Renata Lopes 2021-11-29T18:27:35Zoai:rbc.inca.gov.br:article/1014Revistahttps://rbc.inca.gov.br/index.php/revistaPUBhttps://rbc.inca.gov.br/index.php/revista/oairbc@inca.gov.br0034-71162176-9745opendoar:2021-11-29T18:27:35Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)false
dc.title.none.fl_str_mv The State-of-the-Art of Immunotherapy in the Triple-Negative Breast Cancer Treatment: Main Drugs, Combinations, Mechanisms of Action and Future Perspectives
El Estado del Arte de la Inmunoterapia en el Tratamiento del Cáncer de Mama Triple Negativo: Principales Fármacos, Asociaciones, Mecanismos de Acción y Perspectivas de Futuro
O Estado da Arte da Imunoterapia no Tratamento do Câncer de Mama Triplo-Negativo: Principais Drogas, Associações, Mecanismos de Ação e Perspectivas Futuras
title The State-of-the-Art of Immunotherapy in the Triple-Negative Breast Cancer Treatment: Main Drugs, Combinations, Mechanisms of Action and Future Perspectives
spellingShingle The State-of-the-Art of Immunotherapy in the Triple-Negative Breast Cancer Treatment: Main Drugs, Combinations, Mechanisms of Action and Future Perspectives
Tavares, Dione Fernandes
Imunoterapia
Neoplasias da Mama/terapia
Neoplasias de Mama Triplo Negativas
Biomarcadores
Immunotherapy
Breast Neoplasms/therapy
Triple Negative Breast Neoplasms
Biomarkers
Inmunoterapia
Neoplasias de la Mama/terapia
Neoplasias de la Mama Triple Negativas
Biomarcadores
title_short The State-of-the-Art of Immunotherapy in the Triple-Negative Breast Cancer Treatment: Main Drugs, Combinations, Mechanisms of Action and Future Perspectives
title_full The State-of-the-Art of Immunotherapy in the Triple-Negative Breast Cancer Treatment: Main Drugs, Combinations, Mechanisms of Action and Future Perspectives
title_fullStr The State-of-the-Art of Immunotherapy in the Triple-Negative Breast Cancer Treatment: Main Drugs, Combinations, Mechanisms of Action and Future Perspectives
title_full_unstemmed The State-of-the-Art of Immunotherapy in the Triple-Negative Breast Cancer Treatment: Main Drugs, Combinations, Mechanisms of Action and Future Perspectives
title_sort The State-of-the-Art of Immunotherapy in the Triple-Negative Breast Cancer Treatment: Main Drugs, Combinations, Mechanisms of Action and Future Perspectives
author Tavares, Dione Fernandes
author_facet Tavares, Dione Fernandes
Cardoso-Júnior, Laércio Moreira
Ribeiro, Victoria Chaves
Britto, Renata Lopes
author_role author
author2 Cardoso-Júnior, Laércio Moreira
Ribeiro, Victoria Chaves
Britto, Renata Lopes
author2_role author
author
author
dc.contributor.author.fl_str_mv Tavares, Dione Fernandes
Cardoso-Júnior, Laércio Moreira
Ribeiro, Victoria Chaves
Britto, Renata Lopes
dc.subject.por.fl_str_mv Imunoterapia
Neoplasias da Mama/terapia
Neoplasias de Mama Triplo Negativas
Biomarcadores
Immunotherapy
Breast Neoplasms/therapy
Triple Negative Breast Neoplasms
Biomarkers
Inmunoterapia
Neoplasias de la Mama/terapia
Neoplasias de la Mama Triple Negativas
Biomarcadores
topic Imunoterapia
Neoplasias da Mama/terapia
Neoplasias de Mama Triplo Negativas
Biomarcadores
Immunotherapy
Breast Neoplasms/therapy
Triple Negative Breast Neoplasms
Biomarkers
Inmunoterapia
Neoplasias de la Mama/terapia
Neoplasias de la Mama Triple Negativas
Biomarcadores
description Introduction: Breast cancer is the most commonly diagnosed cancer in women and is one of the leading causes of death from cancer in women worldwide. Despite, or perhaps because of its aggressive nature and current lack of targeted treatments, significant basic research and clinical trials are being conducted to provide new treatment options. Historically, chemotherapy has been the only viable systemic treatment option for early and advanced diseases. However, recently published clinical trials have shown that immunotherapy plays an important role in the treatment paradigm of this devastating clinical condition. Objective: To demonstrate the state-of-the-art results of immunotherapy in the treatment of triple-negative breast cancer. Method: An integrative literature review was carried out between January/2020 and March/2020, in PubMed, SciELO, International Clinical Trials Registry Platform and LILACS databases, using the keywords “Immunotherapy”, “Breast Cancer”, and “Triple Negative Breast Cancer” and its respective correspondents in Portuguese. Results: 465 articles were found; of those, 457 were excluded after applying the methodological criteria. Thus, 8 articles that met the inclusion criteria, showing the main therapeutic agents used, mechanisms of action and therapeutic combinations, remained. 25 clinical trials were found in progress on the International Clinical Trials Registry Platform. Conclusion: Although immunotherapy is somewhat recent, its results with PARP, PD-1 and PD-L1 inhibitors have shown satisfactory results. New trials with subgroups stratified according to specific tumor biomarkers are needed in order to assess if some subgroups have greater benefit to treatment.
publishDate 2021
dc.date.none.fl_str_mv 2021-03-08
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Revisão de literatura
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/1014
10.32635/2176-9745.RBC.2021v67n2.1014
url https://rbc.inca.gov.br/index.php/revista/article/view/1014
identifier_str_mv 10.32635/2176-9745.RBC.2021v67n2.1014
dc.language.iso.fl_str_mv por
eng
language por
eng
dc.relation.none.fl_str_mv https://rbc.inca.gov.br/index.php/revista/article/view/1014/979
https://rbc.inca.gov.br/index.php/revista/article/view/1014/1358
dc.rights.driver.fl_str_mv Copyright (c) 2021 Revista Brasileira de Cancerologia
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2021 Revista Brasileira de Cancerologia
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv INCA
publisher.none.fl_str_mv INCA
dc.source.none.fl_str_mv Revista Brasileira de Cancerologia; Vol. 67 No. 2 (2021): Apr./May/June; e-061014
Revista Brasileira de Cancerologia; Vol. 67 Núm. 2 (2021): abr./mayo/jun.; e-061014
Revista Brasileira de Cancerologia; v. 67 n. 2 (2021): abr./maio/jun.; e-061014
2176-9745
reponame:Revista Brasileira de Cancerologia (Online)
instname:Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron:INCA
instname_str Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
instacron_str INCA
institution INCA
reponame_str Revista Brasileira de Cancerologia (Online)
collection Revista Brasileira de Cancerologia (Online)
repository.name.fl_str_mv Revista Brasileira de Cancerologia (Online) - Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA)
repository.mail.fl_str_mv rbc@inca.gov.br
_version_ 1797042246056411136

Registros relacionados